This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Welcome to Novo Nordisk Rare Diseases Science Hub


The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a non-US healthcare professional.

Tel Aviv University , Tel Aviv, Israel

Gili Kenet is a Pediatric Hematologist, Professor and former Chair of the Hematology Department at the Sackler Medical School, Tel Aviv University.


Professor Kenet received her Medical Degree from the Hebrew University in Jerusalem.  Her research projects have been focused on neonatal hemostasis, childhood stroke and pediatric thrombophilia, as well as the research of new therapy modes applied for people with hemophilia and severe bleeding disorders.  She was awarded national grants for pediatric hematology and cancer research, study of rFVIIa mode of action, epidemiology of inhibitor evolution in hemophilia and for personalized tailoring of bypass agent therapy, and applying global hemostasis assays. Prof. Kenet pioneered in gene therapy clinical trials in Israel and novel non replacement drugs in Hemophilia.


Professor Kenet is the author of over 200 peer reviewed scientific publications, review articles and book chapters.  An active member of the World Federation of Hemophilia, Israeli Society of Pediatric Hematology and Oncology, and the American Society of Hematology, an active reviewer for high impact thrombosis journals and an editorial board member of the Haemophilia journal.  Former Chairperson of the Israeli Society of Thrombosis and Hemostasis and Chairperson of the Pediatric and Peri-natal Hemostasis Scientific Subcommittee of ISTH.  Currently co-chairs the FVIII/FIX and rare bleeding disorders of the SSC of ISTH.